We pressure-tested the idea before we trusted it.
This didn’t start as a finished plan. It started as a question — where is there real, underserved demand in cash-pay medicine? — and an automated process for answering it honestly. That process produced two useful capabilities: a disciplined way to find clinic demand, and a clinic-facing product worth piloting. Here’s the walk-through.
A research engine, not a hunch
Rather than fall in love with a single idea, we built a repeatable validation pipeline: gather live market signals, score an opportunity against fixed gates, then deliberately try to break the thesis before committing. The goal was to fail cheaply on paper instead of expensively in the market.
Source the signal
Automated market and search research mapped where demand was real, rising, and not already owned by an entrenched competitor.
Score against fixed gates
Every candidate was judged on the same criteria — demand, competition, economics, and risk — so enthusiasm couldn’t outvote evidence.
Red-team the survivor
The leading idea was handed to an adversarial review whose only job was to find what kills it. If it survived, we’d build. If not, better to know now.
An engine to get customers — and something to sell them
The work produced two real capabilities that stand on their own. One helps identify qualified clinic demand; the other is a product built for repeatable clinic follow-up.
An engine built to get customers
An automated pipeline that researches a market, ranks an asset, and captures inbound clinic interest — the demand-side muscle of the company. The next milestone is using it to book qualified clinic conversations, not to sell patient leads.
Peptodyssey, the retention product
Software for clinics: structured screening and biomarker tracking workflows that document follow-up context and support retention. The thing clinics stay for once they’re in the door.
We red-teamed our own plan and tightened it
One early structure didn’t survive scrutiny — and we’re glad we caught it on paper. We considered selling patient leads to clinics, and an adversarial review flagged that doing so can be construed as patient brokering under Florida law: an all-payor statute that reaches even cash-pay, with felony-grade exposure, and federal anti-kickback rules on top. So we ruled out that one sale.
To be precise about what that did and didn’t change:
Selling patient leads to clinics
That specific transaction — handing a clinic a patient’s contact info for a fee — is the part the law gates. We don’t do it.
The lead-gen engine + the software
The capability to research, rank, and capture qualified clinic interest remains usable. And selling clinics software is an ordinary B2B sale — no patient referral, no brokering.
That’s the discipline we bring to a regulated space: keep the clinic-acquisition capability, cut the one structure that doesn’t fit, and know the difference.
The regulatory moment works in our favor
As oversight of compounded peptides and GLP-1s evolves, clinics increasingly need clearer documentation around protocol rationale and follow-up. That same pressure is exactly what makes a documentation-and-tracking workflow valuable. We built toward that, not against it.
Tightening oversight
FDA and compliance attention around compounded GLP-1s and peptides has moved quickly, raising the bar for clinic documentation and review.
A documented reason
Clinics want a structured record behind each decision. Peptodyssey is built to produce exactly that, as a byproduct of normal care.
Retention follows
The same structure that documents the rationale gives patients and providers a clearer follow-up record.
The automation behind it
The validation engine that vetted the idea didn’t get thrown away — it became the operating system for the company. The research, content, and intake tooling we built now run the clinic-facing side of the business, so the rigor that picked the model also runs it day to day.
Research & validation
The same engine that scored and stress-tested the opportunity keeps watching the market and the regulatory landscape.
Content & outreach
Automated drafting supports clinician-facing material — reviewed by a human, never auto-published.
Intake & routing
Clinic inquiries are captured and routed cleanly — contact details only, with patient information kept out by design.
We did the homework so the model would hold up
Peptodyssey is what was left after we tried hard to break it: a software business that sells structure to clinics, avoids patient-lead brokering, and earns its keep by making follow-up more repeatable.
Where the regulatory and legal references come from
Two points on this page rest on primary sources: that FDA oversight of compounded peptides and GLP-1s has moved quickly, and that selling patient leads can implicate Florida’s patient-brokering statute. The links below are the underlying references.